Novavax RSV F Vaccine Fails Phase 3 Trial

News   Sep 20, 2016

 
Novavax RSV F Vaccine Fails Phase 3 Trial
 
 
 

RELATED ARTICLES

PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug Discovery

News

Investment to fund expansion of operations and progression of drug target pipeline.

READ MORE

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites

News

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

READ MORE

Vaccine to One Hemorrhagic Virus Could Protect Against Others

News

Scientists report that antibodies made in response to a vaccine against one hemorrhagic fever virus—Junin—can successfully disarm one of its cousins, Machupo, for which there’s currently no vaccine.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE